Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Henlius and Promega Form IVD Collaboration for PD-1 Candidate

publication date: Aug 5, 2021

Shanghai Henlius Biotech will collaborate with Shanghai Promega to provide a companion IVD kit for serplulimab, its anti-PD-1 drug. Henlius will develop Promega's OncoMate™ MSI Dx Analysis System to determine microsatellite instability (MSI) status in solid tumor cancers. Patients with high levels of MSA have been shown to react well to immune checkpoint inhibitors, including PD-1 therapies. Promega is a global research tools company that is headquartered in Wisconsin. Henlius, a Fosun Pharma spin-out, focuses on biologic drug development. More details....

Stock Symbol: (HK: 2696)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital